ZHENG R S , CHEN R , HAN B F , et al . Cancer incidence and mortality in China, 2022 [J ] . Zhonghua Zhong Liu Za Zhi , 2024 , 46 : 221 - 231 .

YANG W J , ZHAO H P , YU Y , et al . Updates on global epidemiology, risk and prognostic factors of gastric cancer [J ] . World J Gastroenterol , 2023 , 29 ( 16 ): 2452 - 2468 . DOI: 10.3748/wjg.v29.i16.2452 http://doi.org/10.3748/wjg.v29.i16.2452 https://www.wjgnet.com/1007-9327/full/v29/i16/2452.htm https://www.wjgnet.com/1007-9327/full/v29/i16/2452.htm

SMYTH E C , NILSSON M , GRABSCH H I , et al . Gastric cancer [J ] . Lancet , 2020 , 396 ( 10251 ): 635 - 648 . DOI: S0140-6736(20)31288-5 http://doi.org/S0140-6736(20)31288-5

SATO H , NOSHIRO H . Report about the present condition of Billroth’s stomach specimens [J ] . Gastric Cancer , 2019 , 22 ( 6 ): 1310 - 1311 . DOI: 10.1007/s10120-019-00987-z http://doi.org/10.1007/s10120-019-00987-z

GHOSSAIN A , GHOSSAIN M A . History of mastectomy before and after Halsted [J ] . J Med Liban , 2009 , 57 ( 2 ): 65 - 71 .

日本胃癌学会 . 胃癌处理规约 [M ] . 10版. 东京 : 金原出版株式会社 , 1979 .

Japanese Gastric Cancer Association . Gastric cancer management protocol [M ] . 10 edition. Tokyo : Kanehara Publishing Co., LTD , 1979 .

CUSCHIERI A , FAYERS P , FIELDING J , et al . Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group [J ] . Lancet , 1996 , 347 ( 9007 ): 995 - 999 . DOI: 10.1016/s0140-6736(96)90144-0 http://doi.org/10.1016/s0140-6736(96)90144-0

BONENKAMP J J , HERMANS J , SASAKO M , et al . Extended lymph-node dissection for gastric cancer [J ] . N Engl J Med , 1999 , 340 ( 12 ): 908 - 914 . DOI: 10.1056/NEJM199903253401202 http://doi.org/10.1056/NEJM199903253401202 http://www.nejm.org/doi/abs/10.1056/NEJM199903253401202 http://www.nejm.org/doi/abs/10.1056/NEJM199903253401202

SONGUN I , PUTTER H , KRANENBARG E M , et al . Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial [J ] . Lancet Oncol , 2010 , 11 ( 5 ): 439 - 449 . DOI: 10.1016/S1470-2045(10)70070-X http://doi.org/10.1016/S1470-2045(10)70070-X

SASAKO M , SANO T , YAMAMOTO S , et al . D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer [J ] . N Engl J Med , 2008 , 359 ( 5 ): 453 - 462 . DOI: 10.1056/NEJMoa0707035 http://doi.org/10.1056/NEJMoa0707035 http://www.nejm.org/doi/abs/10.1056/NEJMoa0707035 http://www.nejm.org/doi/abs/10.1056/NEJMoa0707035

TSUBURAYA A , MIZUSAWA J , TANAKA Y , et al . Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis [J ] . Br J Surg , 2014 , 101 ( 6 ): 653 - 660 . DOI: 10.1002/bjs.9484 http://doi.org/10.1002/bjs.9484

KUROKAWA Y , TAKEUCHI H , DOKI Y , et al . Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study [J ] . Ann Surg , 2021 , 274 ( 1 ): 120 - 127 . DOI: 10.1097/SLA.0000000000003499 http://doi.org/10.1097/SLA.0000000000003499 https://journals.lww.com/10.1097/SLA.0000000000003499 https://journals.lww.com/10.1097/SLA.0000000000003499

徐泽宽 , 李铮 , 徐皓 . 从2023年国际胃癌大会看胃癌外科治疗进展与发展趋势 [J ] . 中国实用外科杂志 , 2023 , 43 ( 9 ): 971 - 974 .

XU Z K , LI Z , XU H . Progress and trends of surgical treatment for gastric cancer from the International Gastric Cancer Congress 2023(IGCC 2023) [J ] . Chin J Pract Surg , 2023 , 43 ( 9 ): 971 - 974 .

KITANO S , ISO Y , MORIYAMA M , et al . Laparoscopy-assisted billroth Ⅰ gastrectomy [J ] . Surg Laparosc Endosc , 1994 , 4 ( 2 ): 146 - 148 .

YOUNG K , MO H , LEE H H , et al . Laproscopic surgery for gastric cancer [M ] //Management of Gastric Cancer. InTech , 2011 .

KIM H H , HAN S U , KIM M C , et al . Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage Ⅰ gastric cancer: the KLASS-01 randomized clinical trial [J ] . JAMA Oncol , 2019 , 5 ( 4 ): 506 - 513 . DOI: 10.1001/jamaoncol.2018.6727 http://doi.org/10.1001/jamaoncol.2018.6727 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727

KATAI H , MIZUSAWA J , KATAYAMA H , et al . Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial [J ] . Lancet Gastroenterol Hepatol , 2020 , 5 ( 2 ): 142 - 151 .

YU J , HUANG C M , SUN Y H , et al . Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial [J ] . JAMA , 2019 , 321 ( 20 ): 1983 - 1992 . DOI: 10.1001/jama.2019.5359 http://doi.org/10.1001/jama.2019.5359 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.5359 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.5359

HYUNG W J , YANG H K , HAN S U , et al . A feasibility study of laparoscopic total gastrectomy for clinical stage Ⅰ gastric cancer: a prospective multi-center phase Ⅱ clinical trial, KLASS 03 [J ] . Gastric Cancer , 2019 , 22 ( 1 ): 214 - 222 . DOI: 10.1007/s10120-018-0864-4 http://doi.org/10.1007/s10120-018-0864-4

KATAI H , MIZUSAWA J , KATAYAMA H , et al . Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰ gastric cancer: Japan Clinical Oncology Group study JCOG1401 [J ] . Gastric Cancer , 2019 , 22 ( 5 ): 999 - 1008 . DOI: 10.1007/s10120-019-00929-9 http://doi.org/10.1007/s10120-019-00929-9

LIU F L , HUANG C M , XU Z K , et al . Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: the CLASS02 multicenter randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 10 ): 1590 - 1597 . DOI: 10.1001/jamaoncol.2020.3152 http://doi.org/10.1001/jamaoncol.2020.3152 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769669 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769669

HASHIZUME M , KONISHI K , TSUTSUMI N , et al . A new era of robotic surgery assisted by a computer-enhanced surgical system [J ] . Surgery , 2002 , 131 ( 1 Suppl ): S330-S333.

LI Z Y , ZHOU Y B , LI T Y , et al . Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a multicenter cohort study of 5 402 patients in China [J ] . Ann Surg , 2023 , 277 ( 1 ): e87-e95.

OJIMA T , NAKAMURA M , HAYATA K , et al . Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: a randomized clinical trial [J ] . JAMA Surg , 2021 , 156 ( 10 ): 954 - 963 . DOI: 10.1001/jamasurg.2021.3182 http://doi.org/10.1001/jamasurg.2021.3182 https://jamanetwork.com/journals/jamasurgery/fullarticle/2783555 https://jamanetwork.com/journals/jamasurgery/fullarticle/2783555

ZONG L , ABE M , SETO Y , et al . The challenge of screening for early gastric cancer in China [J ] . Lancet , 2016 , 388 ( 10060 ): 2606.

中国胃肠肿瘤外科联盟 . 中国胃肠肿瘤外科联盟数据报告(2014—2016) [J ] . 中国实用外科杂志 , 2018 , 38 ( 1 ): 90 - 93 . DOI: 10.19538/j.cjps.issn1005-2208.2018.01.20 http://doi.org/10.19538/j.cjps.issn1005-2208.2018.01.20

China Gastrointestinal Cancer Surgery Union . Data report of China Gastrointestinal Cancer Surgery Union (2014-2016) [J ] . Chin J Pract Surg , 2018 , 38 ( 1 ): 90 - 93 .

SASAKO M , SANO T , YAMAMOTO S , et al . Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial [J ] . Lancet Oncol , 2006 , 7 ( 8 ): 644 - 651 . DOI: 10.1016/S1470-2045(06)70766-5 http://doi.org/10.1016/S1470-2045(06)70766-5

SANO T , SASAKO M , MIZUSAWA J , et al . Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma [J ] . Ann Surg , 2017 , 265 ( 2 ): 277 - 283 . DOI: 10.1097/SLA.0000000000001814 http://doi.org/10.1097/SLA.0000000000001814

KUROKAWA Y , DOKI Y , MIZUSAWA J , et al . Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial [J ] . Lancet Gastroenterol Hepatol , 2018 , 3 ( 7 ): 460 - 468 .

SAKURAMOTO S , SASAKO M , YAMAGUCHI T , et al . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [J ] . N Engl J Med , 2007 , 357 ( 18 ): 1810 - 1820 . DOI: 10.1056/NEJMoa072252 http://doi.org/10.1056/NEJMoa072252 http://www.nejm.org/doi/abs/10.1056/NEJMoa072252 http://www.nejm.org/doi/abs/10.1056/NEJMoa072252

BANG Y J , KIM Y W , YANG H K , et al . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J ] . Lancet , 2012 , 379 ( 9813 ): 315 - 321 . DOI: 10.1016/S0140-6736(11)61873-4 http://doi.org/10.1016/S0140-6736(11)61873-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734 https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734

CUNNINGHAM D , ALLUM W H , STENNING S P , et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J ] . N Engl J Med , 2006 , 355 ( 1 ): 11 - 20 . DOI: 10.1056/NEJMoa055531 http://doi.org/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531

AL-BATRAN S E , HOMANN N , PAULIGK C , et al . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J ] . Lancet , 2019 , 393 ( 10184 ): 1948 - 1957 . DOI: 10.1016/S0140-6736(18)32557-1 http://doi.org/10.1016/S0140-6736(18)32557-1 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571

ZHANG X T , LIANG H , LI Z Y , et al . Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial [J ] . Lancet Oncol , 2021 , 22 ( 8 ): 1081 - 1092 . DOI: 10.1016/S1470-2045(21)00297-7 http://doi.org/10.1016/S1470-2045(21)00297-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002977 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002977

KANG Y K , YOOK J H , PARK Y K , et al . PRODIGY: a phase Ⅲ study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer [J ] . J Clin Oncol , 2021 , 39 ( 26 ): 2903 - 2913 . DOI: 10.1200/JCO.20.02914 http://doi.org/10.1200/JCO.20.02914 https://ascopubs.org/doi/10.1200/JCO.20.02914 https://ascopubs.org/doi/10.1200/JCO.20.02914

BANG Y J , VAN CUTSEM E , FEYEREISLOVA A , et al . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J ] . Lancet , 2010 , 376 ( 9742 ): 687 - 697 . DOI: 10.1016/S0140-6736(10)61121-X http://doi.org/10.1016/S0140-6736(10)61121-X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X

SHAH M A , SHITARA K , AJANI J A , et al . Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial [J ] . Nat Med , 2023 , 29 ( 8 ): 2133 - 2141 . DOI: 10.1038/s41591-023-02465-7 http://doi.org/10.1038/s41591-023-02465-7

HOFHEINZ R D , HEGEWISCH-BECKER S , KUNZMANN V , et al . Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase Ⅱ trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group [J ] . Int J Cancer , 2021 , 149 ( 6 ): 1322 - 1331 . DOI: 10.1002/ijc.v149.6 http://doi.org/10.1002/ijc.v149.6 https://onlinelibrary.wiley.com/toc/10970215/149/6 https://onlinelibrary.wiley.com/toc/10970215/149/6

RIVERA F , IZQUIERDO-MANUEL M , GARCÍA-ALFONSO P , et al . Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase Ⅱ trial [J ] . Eur J Cancer , 2021 , 145 : 158 - 167 . DOI: 10.1016/j.ejca.2020.12.005 http://doi.org/10.1016/j.ejca.2020.12.005 https://linkinghub.elsevier.com/retrieve/pii/S0959804920314179 https://linkinghub.elsevier.com/retrieve/pii/S0959804920314179

JANJIGIAN Y Y , SHITARA K , MOEHLER M , et al . First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial [J ] . Lancet , 2021 , 398 ( 10294 ): 27 - 40 . DOI: 10.1016/S0140-6736(21)00797-2 http://doi.org/10.1016/S0140-6736(21)00797-2

SHITARA K , VAN CUTSEM E , BANG Y J , et al . Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 10 ): 1571 - 1580 . DOI: 10.1001/jamaoncol.2020.3370 http://doi.org/10.1001/jamaoncol.2020.3370 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769922 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769922

SHITARA K , MOEHLER M H , AJANI J A , et al . Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649 [C ] . Chicago: ASCO , 2024 .

XU J M , JIANG H P , PAN Y Y , et al . Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial [J ] . JAMA , 2023 , 330 ( 21 ): 2064 - 2074 . DOI: 10.1001/jama.2023.19918 http://doi.org/10.1001/jama.2023.19918

TERASHIMA M , KANG Y K , KIM Y W , et al . ATTRACTION-5: a phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage Ⅲ (pStage Ⅲ) gastric or gastroesophageal junction (G/GEJ) cancer [J ] . J Clin Oncol , 2023 , 41 ( 16 _suppl): 4000.

SHITARA K , RHA S Y , WYRWICZ L S , et al . Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study [J ] . Lancet Oncol , 2024 , 25 ( 2 ): 212 - 224 . DOI: 10.1016/S1470-2045(23)00541-7 http://doi.org/10.1016/S1470-2045(23)00541-7

JANJIGIAN Y Y , AL-BATRAN S E , WAINBERG Z A , et al . Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study [J ] . J Clin Oncol , 2024 , 42 ( 3_suppl ): LBA246.

JANJIGIAN Y Y , KAWAZOE A , BAI Y X , et al . Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial [J ] . Lancet , 2023 , 402 ( 10418 ): 2197 - 2208 . DOI: 10.1016/S0140-6736(23)02033-0 http://doi.org/10.1016/S0140-6736(23)02033-0

AL-BATRAN S E , HOMANN N , PAULIGK C , et al . Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial [J ] . JAMA Oncol , 2017 , 3 ( 9 ): 1237 - 1244 . DOI: 10.1001/jamaoncol.2017.0515 http://doi.org/10.1001/jamaoncol.2017.0515 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0515 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0515

LUO H Y , XU G L , LI C F , et al . Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study [J ] . Lancet Oncol , 2019 , 20 ( 12 ): 1645 - 1654 . DOI: S1470-2045(19)30637-0 http://doi.org/S1470-2045(19)30637-0

DONG D , FANG M J , TANG L , et al . Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study [J ] . Ann Oncol , 2020 , 31 ( 7 ): 912 - 920 . DOI: S0923-7534(20)39294-2 http://doi.org/S0923-7534(20)39294-2

DONG D , TANG L , LI Z Y , et al . Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer [J ] . Ann Oncol , 2019 , 30 ( 3 ): 431 - 438 . DOI: S0923-7534(19)31081-6 http://doi.org/S0923-7534(19)31081-6

SUNDAR R , BARR KUMARAKULASINGHE N , HUAK CHAN Y , et al . Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase Ⅲ SAMIT trial [J ] . Gut , 2022 , 71 ( 4 ): 676 - 685 . DOI: 10.1136/gutjnl-2021-324060 http://doi.org/10.1136/gutjnl-2021-324060 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-324060 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-324060

KATHER J N , PEARSON A T , HALAMA N , et al . Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer [J ] . Nat Med , 2019 , 25 ( 7 ): 1054 - 1056 . DOI: 10.1038/s41591-019-0462-y http://doi.org/10.1038/s41591-019-0462-y

CHEN Q Y , XIE J W , ZHONG Q , et al . Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial [J ] . JAMA Surg , 2020 , 155 ( 4 ): 300 - 311 . DOI: 10.1001/jamasurg.2019.6033 http://doi.org/10.1001/jamasurg.2019.6033 https://jamanetwork.com/journals/jamasurgery/fullarticle/2761887 https://jamanetwork.com/journals/jamasurgery/fullarticle/2761887

CHEN Q Y , ZHONG Q , LIU Z Y , et al . Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: long-term outcomes of a phase 3 randomised clinical trial [J ] . Nat Commun , 2023 , 14 ( 1 ): 7413.